MedTrace Logo

Phase I/II Trial to Evaluate Safety, Tolerability and Pharmacokinetic Profile of HM61713 in NSCLC Patients

NCT01588145 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 273

Last updated 2018-04-24

No results posted yet for this study

Summary

The main objective of this study is to evaluate the safety and tolerability of HM61713.

Conditions

  • Non Small Cell Lung Cancer

Interventions

DRUG

HM61713

BID or QD, PO X 21 day cycle Number of cycles: until progression or unacceptable toxicity develops

Sponsors & Collaborators

  • Hanmi Pharmaceutical Company Limited

    lead INDUSTRY

Principal Investigators

  • Dong-Wan Kim, MD PhD · Seoul National University Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-03-31
Primary Completion
2017-08-31
Completion
2017-08-31

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01588145 on ClinicalTrials.gov